Match!

A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.

Published on Mar 18, 2020in Science Advances11.5
· DOI :10.1126/SCIADV.AAW6071
Qianqian Ni8
Estimated H-index: 8
(NU: Nanjing University),
Fuwu Zhang23
Estimated H-index: 23
(NIH: National Institutes of Health)
+ 9 AuthorsGuangming Lu46
Estimated H-index: 46
(NU: Nanjing University)
Abstract
Neoantigen vaccines have been enthusiastically pursued for personalized cancer immunotherapy while vast majority of neoantigens have no or low immunogenicity. Here, a bi-adjuvant neoantigen nanovaccine (banNV) that codelivered a peptide neoantigen (Adpgk) with two adjuvants [Toll-like receptor (TLR) 7/8 agonist R848 and TLR9 agonist CpG] was developed for potent cancer immunotherapy. Specifically, banNVs were prepared by a nanotemplated synthesis of concatemer CpG, nanocondensation with cationic polypeptides, and then physical loading with hydrophobic R848 and Adpgk. The immunogenicity of the neoantigen was profoundly potentiated by efficient codelivery of neoantigen and dual synergistic adjuvants, which is accompanied by reduced acute systemic toxicity. BanNVs sensitized immune checkpoint programmed death receptor 1 (PD-1) on T cells, therefore, a combination of banNVs with aPD-1 conspicuously induced the therapy response and led to complete regression of 70% neoantigen-specific tumors without recurrence. We conclude that banNVs are promising to optimize personalized therapeutic neoantigen vaccines for cancer immunotherapy.
  • References (45)
  • Citations (0)
📖 Papers frequently viewed together
7 Citations
20186.01JCI insight
15 Authors (Heather L. Kinkead, ..., Neeha Zaidi)
13 Citations
1 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References45
Newest
#1Vivek Verma (GUMC: Georgetown University Medical Center)H-Index: 1
#2Rajeev K. Shrimali (University of Texas MD Anderson Cancer Center)H-Index: 12
Last. Samir N. Khleif (GUMC: Georgetown University Medical Center)H-Index: 1
view all 28 authors...
Understanding resistance to antibody to programmed cell death protein 1 (PD-1; anti-PD-1) is crucial for the development of reversal strategies. In anti-PD-1-resistant models, simultaneous anti-PD-1 and vaccine therapy reversed resistance, while PD-1 blockade before antigen priming abolished therapeutic outcomes. This was due to induction of dysfunctional PD-1+CD38hi CD8+ cells by PD-1 blockade in suboptimally primed CD8 cell conditions induced by tumors. This results in erroneous T cell recepto...
5 CitationsSource
#1Shan GaoH-Index: 3
#2Dongjuan YangH-Index: 3
Last. Kai ShiH-Index: 12
view all 9 authors...
5 CitationsSource
#1Jinyang Li (UPenn: University of Pennsylvania)H-Index: 4
#2Katelyn T. Byrne (UPenn: University of Pennsylvania)H-Index: 14
Last. Ben Z. StangerH-Index: 51
view all 29 authors...
Summary The biological and functional heterogeneity between tumors—both across and within cancer types—poses a challenge for immunotherapy. To understand the factors underlying tumor immune heterogeneity and immunotherapy sensitivity, we established a library of congenic tumor cell clones from an autochthonous mouse model of pancreatic adenocarcinoma. These clones generated tumors that recapitulated T cell-inflamed and non-T-cell-inflamed tumor microenvironments upon implantation in immunocompet...
52 CitationsSource
#1Rui Kuai (UM: University of Michigan)H-Index: 13
#2Wenmin Yuan (UM: University of Michigan)H-Index: 11
Last. James Moon (UM: University of Michigan)H-Index: 59
view all 8 authors...
Although immune checkpoint blockade has shown initial success for various cancers, only a small subset of patients benefits from this therapy. Some chemotherapeutic drugs have been reported to induce antitumor T cell responses, prompting a number of clinical trials on combination chemoimmunotherapy. However, how to achieve potent immune activation with traditional chemotherapeutics in a manner that is safe, effective, and compatible with immunotherapy remains unclear. We show that high-density l...
29 CitationsSource
#1Judith A. Seidel (Kyoto University)H-Index: 4
#2Atsushi Otsuka (Kyoto University)H-Index: 22
Last. Kenji Kabashima (Kyoto University)H-Index: 53
view all 3 authors...
Melanoma, a skin cancer associated with high mortality rates, is highly radio- and chemotherapy resistant but can also be very immunogenic. These circumstances have led to a recent surge in research into therapies aiming to boost anti-tumor immune responses in cancer patients. Among these immunotherapies, neutralizing antibodies targeting the immune checkpoints CTLA-4 and PD-1 are being hailed as particularly successful. These antibodies have resulted in dramatic improvements in disease outcome ...
84 CitationsSource
#1Kacper Skakuj (International Institute of Minnesota)H-Index: 1
#2Shuya Wang (NU: Northwestern University)H-Index: 3
Last. Chad A. Mirkin (International Institute of Minnesota)H-Index: 137
view all 6 authors...
Spherical nucleic acids (SNAs) can be potent sequence-specific stimulators of antigen presenting cells (APCs). When loaded with peptide antigens, they can be used to activate the immune system to train T-cells to specifically kill cancer cells. Herein, the role of peptide chemical conjugation to the DNA, which is used to load SNAs with antigens via hybridization, is explored in the context of APC activation. Importantly, though the antigen chemistry does not impede TLR-9 regulated APC activation...
9 CitationsSource
#1Yanhong ChuH-Index: 1
#2Qin LiuH-Index: 11
Last. Baorui LiuH-Index: 34
view all 4 authors...
6 CitationsSource
#1Sattva S. Neelapu (University of Texas MD Anderson Cancer Center)H-Index: 42
#2Frederick L. Locke (USF: University of South Florida)H-Index: 15
Last. William Y. GoH-Index: 2
view all 40 authors...
BackgroundIn a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy. MethodsIn this multicenter, phase 2 trial, we enrolled 111 patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, or transformed follicular lymphoma who had refractory disease despite undergoing recommended prior therapy. Patie...
493 CitationsSource
#1Yuchen Fan (UM: University of Michigan)H-Index: 11
#2Rui Kuai (UM: University of Michigan)H-Index: 13
Last. James MoonH-Index: 59
view all 6 authors...
Despite their potential, conventional whole-cell cancer vaccines prepared by freeze–thawing or irradiation have shown limited therapeutic efficacy in clinical trials. Recent studies have indicated that cancer cells treated with certain chemotherapeutics, such as mitoxantrone, can undergo immunogenic cell death (ICD) and initiate antitumor immune responses. However, it remains unclear how to exploit ICD for cancer immunotherapy. Here, we present a new material-based strategy for converting immuno...
31 CitationsSource
#1Guizhi Zhu (NIH: National Institutes of Health)H-Index: 38
#2Geoffrey M. Lynn (Vaccine Research Center)H-Index: 1
Last. Xiaoyuan Chen (NIH: National Institutes of Health)H-Index: 112
view all 25 authors...
Subunit vaccines have been investigated in over 1000 clinical trials of cancer immunotherapy, but have shown limited efficacy. Nanovaccines may improve efficacy but have rarely been clinically translated. By conjugating molecular vaccines with Evans blue (EB) into albumin-binding vaccines (AlbiVax), here we develop clinically promising albumin/AlbiVax nanocomplexes that self-assemble in vivo from AlbiVax and endogenous albumin for efficient vaccine delivery and potent cancer immunotherapy. PET p...
37 CitationsSource
Cited By0
Newest